Gong Qi, Tong Barbara, Strasak Alexander, Fang Liang
Amgen Inc., South San Francisco, CA, USA.
Pharm Stat. 2014 Mar-Apr;13(2):136-44. doi: 10.1002/pst.1611. Epub 2014 Feb 11.
As an important aspect of the clinical evaluation of an investigational therapy, safety data are routinely collected in clinical trials. To date, the analysis of safety data has largely been limited to descriptive summaries of incidence rates or contingency tables aiming to compare simple rates between treatment arms. Many have argued that this traditional approach failed to take into account important information including severity, onset time, and multiple occurrences of a safety event. In addition, premature treatment discontinuation due to excessive toxicity causes informative censoring and may lead to potential bias in the interpretation of safety events. In this article, we propose a framework to summarize safety data with mean frequency function and compare safety events of interest between treatments with a generalized log-rank test, taking into account the aforementioned characteristics ignored in traditional analysis approaches. In addition, a multivariate generalized log-rank test to compare the overall safety profile of different treatments is proposed. In the proposed method, safety events are considered to follow a recurrent event process with a terminal event for each patient. The terminal event is modeled by a process of two types of competing risks: safety events of interest and other terminal events. Statistical properties of the proposed method are investigated via simulations. An application is presented with data from a phase II oncology trial.
作为研究性治疗临床评估的一个重要方面,安全性数据在临床试验中会常规收集。迄今为止,安全性数据的分析很大程度上局限于发病率的描述性总结或列联表,旨在比较各治疗组之间的简单发生率。许多人认为,这种传统方法没有考虑到包括严重程度、发病时间和安全事件的多次发生等重要信息。此外,由于毒性过大导致的过早治疗中断会造成信息删失,并可能导致在解释安全事件时产生潜在偏差。在本文中,我们提出了一个用平均频率函数总结安全性数据的框架,并使用广义对数秩检验比较各治疗组之间感兴趣的安全事件,同时考虑到传统分析方法中忽略的上述特征。此外,还提出了一种用于比较不同治疗总体安全性概况的多变量广义对数秩检验。在所提出的方法中,安全事件被认为遵循一个复发事件过程,每个患者有一个终末事件。终末事件由两种竞争风险的过程建模:感兴趣的安全事件和其他终末事件。通过模拟研究了所提出方法的统计特性,并给出了一项II期肿瘤学试验数据的应用实例。